Post by
Roller007 on Jul 22, 2016 9:58pm
Shorting pharma
It's all about the SEC to be imposing new rules regarding non GAAP reporting as its a practice that has been widely abused in the pharma sector. Results will obviously have material impact on Cxr.
I'm actually hoping this breaks $25 to flush out a lot of the jittery investors and to see if any buyers step in at that point. Personally I will wait until I hear directly from MT as the noise around the possibility of fraudulent practices in cxr is getting really loud.
Comment by
FullReversal on Jul 23, 2016 2:52pm
I think you've nailed it. Is the "the noise around the possibility of fraudulent practices" from credible places or just from professional bashers/shorters/private equity? I get reports from RBC Market Research with the Analyst doign weekly scripts reviews, shouldn't they be addressing these bigger questions instead.
Comment by
LatticeInExile on Jul 23, 2016 3:00pm
This post has been removed in accordance with Community Policy